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Abstract
Background Hyperbaricoxygentherapy(HBOT)isusedto
treat various wound types. However, the possible beneﬁcial
and harmful effects of HBOT for acute wounds are unclear.
Methods We undertook a systematic review to evaluate
the effectiveness of HBOT compared to other interventions
on wound healing and adverse effects in patients with acute
wounds. To detect all available randomized controlled
trials (RCTs) we searched ﬁve relevant databases up to
March 2010. Trial selection, quality assessment, data
extraction, and data synthesis were conducted by two of the
authors independently.
Results We included ﬁve trials, totaling 360 patients.
These trials, with some methodologic ﬂaws, included dif-
ferent kinds of wound and focused on different outcome
parameters, which prohibited meta-analysis. A French trial
(n = 36 patients) reported that signiﬁcantly more crush
wounds healed with HBOT than with sham HBOT [relative
risk (RR) 1.70, 95% conﬁdence interval (CI) 1.11–2.61].
Moreover, there were signiﬁcantly fewer additional surgical
procedures required with HBOT (RR 1.60, 95% CI
1.03–2.50), and there was signiﬁcantly less tissue necrosis
(RR 1.70, 95% CI 1.11–2.61). In one of two American trials
(n = 141) burn wounds healed signiﬁcantly quicker with
HBOT (P\0.005) than with routine burn care. A British
trial (n = 48) compared HBOT with usual care. HBOT
resulted in a signiﬁcantly higher percentage of healthy graft
area in split skin grafts (RR 3.50, 95% CI 1.35–9.11). In a
Chinesetrial(n = 145)HBOTdidnotsigniﬁcantlyimprove
ﬂap survival in patients with limb skin defects.
Conclusions HBOT, if readily available, appears effec-
tive for the management of acute, difﬁcult to heal wounds.
This article is based on a Cochrane review ﬁrst published in The
Cochrane Library 2010, Issue 10 (see http://www.thecochranelibrary.
com/ for information). Cochrane reviews are regularly updated as new
evidence emerges and in response to feedback; and The Cochrane
Library should be consulted for the most recent version of the review.
The results of a Cochrane review can be interpreted differently,
depending on people’s perspectives and circumstances. Please con-
sider the conclusions presented carefully. They are the opinions of
review authors and are not necessarily shared by The Cochrane
Collaboration. This systematic review has been prepared under the
aegis of The Cochrane Collaboration, an international organization
that aims to help people make well-informed decisions about health
care by preparing, maintaining, and promoting the accessibility of
systematic reviews of the effects of health care interventions. The
Collaboration’s publication policy permits journals to publish
reviews, with priority if required, but permits The Cochrane Collab-
oration also to publish and disseminate such reviews. Cochrane
reviews cannot be subject to the exclusive copyright requested by
some journals.
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Acute wounds are characterized by breakdown of the
integrity of the soft tissue envelope surrounding any por-
tion of the body [1] and are mostly subsequent to a surgical
intervention or trauma. Such wounds occur more fre-
quently than chronic wounds [2]. Most acute wounds heal
without difﬁculty. However, some are subject to factors
that impede healing, such as poor local blood and oxygen
supply, infection, or damage to the vasculature. If one of
these complicating factors occurs, these wounds can be
considered potential problem wounds with an extended
healing time. In these cases, more speciﬁc care is needed.
Hyperbaric oxygen therapy (HBOT)—delivering 100%
oxygen at pressures above one atmosphere—is thought to
assist wound healing, as it delivers a signiﬁcantly increased
amount of oxygen to the skin and surrounding tissues
[3, 4]. For this reason, HBOT has been used as a treatment
for various chronic and acute wounds [5–7]. HBOT was
shown to be effective for patients with diabetic foot ulcers,
and it signiﬁcantly reduced the risk of major amputation
and improved the chance of healing at 1 year [6, 8]. Two
other Cochrane systematic reviews showed that the
potential value of HBOT for open fractures and burns was
unclear [7, 9]. Another literature review by Goldman
showed some evidence that HBOT promotes healing of
arterial ulcers, calciphylactic ulcers, refractory vasculitic
ulcers, and osteomyelitis, as well as the successful ‘‘take’’
of compromised ﬂaps and grafts [10]. However, that review
included randomized clinical trials (RCTs), nonrandomized
trials (CCTs), cohort studies, retrospective analyses, and
case series. Inclusion of the latter study designs and the fact
it was a single-author review may produce results that are
at a considerable risk of bias.
Evidence regarding the effectiveness of HBOT for acute
wounds has never been appreciated systematically. We
therefore carried out a Cochrane systematic review to
answer the following question: Is HBOT more effective
than other types of treatment (e.g., usual care, sham HBOT,
different intensities of HBOT, or different numbers of
treatment applications) for acute wounds in terms of wound
healing, adverse effects, pain, and cost?
Methods
Protocol and registration
Methods ofthe analysisand inclusion criteriawere speciﬁed
in advance and documented in a protocol described else-
where [11]. Here, our methods and results are summarized
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement [12, 13].
Eligibility criteria
In this review, we included all RCTs that evaluated the
effects of HBOT as treatment for acute wounds in adult
patients. These RCTs compared HBOT with any other
intervention or sham HBOT, or they make comparisons
between different intensities of HBOT or the use different
numbers of treatment applications. We included such RCTs
if they assessed at least one of the following primary out-
come parameters: wound healing and adverse effects. As
secondary outcome parameters, we recorded mortality,
pain scores, quality of life, patient satisfaction, activities of
daily living, increase in transcutaneous oxygen pressure
(tcPO2), amputation rate, length of hospital stay, and cost.
Information sources
The RCTs were identiﬁed by searching the following dat-
abases: Cochrane Wounds Group Specialised Register,
Ovid Medline, Ovid Embase, and EBSCO Cinahl up to
March 2010, and the Cochrane Central Register of Con-
trolled Trials (CENTRAL) up to issue 1, 2010. The search
strategy is detailed elsewhere [11]. Furthermore, we used
our wound expert network to check for ongoing or
unpublished trials. We also screened the reference lists of
all included articles to identify additional relevant trials.
We used no restriction on language, publication data, or
publication status.
Study selection
Two review authors independently selected potentially
relevant trials based on the titles and abstracts of the arti-
cles retrieved by the search. These authors were not
masked for any information about the article, such as the
publishing journal, the authors, the institution, or the
magnitude or direction of the results.
Full-text versions of the articles were obtained if they
matched the inclusion criteria or if further scrutiny was
needed about eligibility. The ﬁnal selection of trials to be
included was made independently by the same review
authors. A third review author was involved in case of any
discrepancies.
Data collection process
Two authors independently extracted and summarized
characteristics and data from the included trials. Dis-
agreements were resolved by discussion between the two
review authors; if no agreement could be reached, a third
author would decide. We contacted one author to obtain
missing information but received no response. Data from
trials published in duplicate were included only once.
536 World J Surg (2011) 35:535–542
123Risk of bias in individual studies
The methodologic quality of each trial was determined by
two of the authors independently. We used the Cochrane
Collaboration appraisal tool to assess risk of bias [14]. This
involves consideration of six quality items: sequence gen-
eration, allocation concealment, blinding, incomplete out-
come data, selective reporting, and ‘‘other’’ potential
sources of bias [14]. Again, a third review author arbitrated
any discrepancies.
Data items
From each included study, information was extracted about
(1) characteristics of trial participants and inclusion and
exclusion criteria; (2) type of intervention (including type,
dose, duration, and frequency of the treatment) versus
control intervention; (3) type of outcome.
Summary measures and methods of analysis
Quantitative data were entered and analyzed in RevMan
5.0.24 (Cochrane Collaboration, Oxford, UK) by one author
and checked by another. We calculated summary estimates
of the treatment effects with 95% conﬁdence intervals (95%
CI) for every comparison. For continuous outcome param-
eters, we calculated the mean differences (MD) when
appropriate. For dichotomous outcome parameters we cal-
culated the risk ratio (RR). To present the number needed to
treat (NNT), the risk difference (RD) was calculated.
Results
Study selection
The search provided a total of 137 publications. The study
inclusion process is shown in Fig. 1. Five RCTs fulﬁlled
our inclusion criteria. No new RCTs were found by refer-
ence checking. Also, no unpublished relevant RCTs were
obtained.
Characteristics of included studies
Participants and intervention
FouroftheﬁveincludedtrialswereinEnglish.Onetrialwas
translated from Chinese into Dutch by a national translation
institute. Trials ranged in size from 16 to 135 patients,
totaling 360 patients. HBOT was applied for various indi-
cations: crush injuries [15], burns [16, 17], split-skin grafts
(SSG) [18], and ﬂap grafting for limb skin defects [19]. The
type of HBOT chamber and the duration and dose of the
treatmentweredifferentamongthetrials.Inaddition,HBOT
was compared to other treatments (Table 1).
Primary and secondary outcomes
In four trials the primary outcome assessed was wound
healing,although measureddifferently.Inonetriallengthof
hospital stay was described as the primary outcome [16].
Adverse effects (including new surgical procedures and
amputation rates) and length of hospital stay were described
in only two trials [15, 16]. Mortality was described twice
[16, 17]. Other outcomes were not reported (Table 1).
Risk of bias within studies
The methodologic quality of the trials was moderate.
Hence, their internal validity was reasonable (Table 2).
Only one of the trials reported their method of randomi-
zation [17]. As a consequence, we could not appreciate
allocation concealment in the other trials. Bouachour et al.
[15] and Hart et al. [17] blinded care provider, patients, and
outcome assessor to treatment allocation. Patients and care
providers were not blinded in the trial of Brannen et al., and
blinding of the outcome assessor was unclear [16]. Perrins
blinded the surgeon to treatment allocation [18] and Xie
and Li reported that no one was blinded [19]. All ran-
domized participants were analyzed in the group to which
they had been allocated in the trials of Bouachour et al.
[15] and Xie and Li [19]. However, in Perrins’ trial two
patients were excluded from the analysis [18]. Neverthe-
less, we were able to perform an intention-to-treat analysis
post hoc. Furthermore, in the trials of Brannen et al. [16]
and Hart et al. [17], it was unclear if they used an intention
to treat-analysis for all the endpoints.
Hart et al. [17], Perrins [18], and Xie and Li [19] did not
report the characteristics of the participants at baseline.
Hence, we were unable to judge baseline comparability.
Bouachouretal.[15]andHartetal.[17]weresupportedbya
research grant received from their hospital but had no
ﬁnancialconﬂictofinterestwithrespecttothetrialoutcome.
Quantitative data
The trials varied markedly in terms of wound types,
comparator treatments, and outcome parameters. There-
fore, the clinical heterogeneity was substantial, so we
focused on describing individual trial results, applicability,
and limitations rather than using a meta-analysis.
Crush injuries
Bouachour et al. [15] studied HBOT in patients with crush
injuries [15]. In this French trial, complete wound healing
World J Surg (2011) 35:535–542 537
123(without tissue necrosis requiring surgical excision) was
achieved in 17 patients (94%) treated with HBOT versus
10 patients (56%) in the sham-HBOT group, showing a
statistically signiﬁcant difference in favor of HBOT ther-
apy (RR 1.70; 95% CI 1.11–2.61; NNT 3). However, they
found no statistical difference between the two groups in
time to complete healing (mean ± SD) 50.2 ± 21.1 days
in the HBOT group versus 55.8 ± 19.9 days in the sham-
HBOT group (MD 5.60; 95% CI 19.00–7.80).
Bouachour et al. [15] also compared HBOT with sham-
HBOT in terms of adverse effects. Two additional surgical
procedures (in one patient) were needed in the HBOT
group versus eight (in six patients) in the sham-HBOT
group (RR 1.60, 95% CI 1.03–2.50; NNT 3), as the ﬁrst
operation did not have the desired effect. In addition, one
patient in the HBOT group versus eight patients in the
sham-HBOT group developed necrotic tissue (RR 1.70,
95% CI 1.11–2.61; NNT 3). No amputations occurred in
the HBOT group versus two amputations in the sham-
HBOT group (RR 1.12, 95% CI 0.93–1.36) and no sig-
niﬁcant differences were observed between the two groups
for length of hospital stay (MD 0.50; 95% CI 9.96–8.96).
Other (secondary) endpoints were not reported.
Burns
Brannen et al. [16] and Hart et al. [17] studied HBOT in
burn patients in the United States. Brannen et al. did not
study wound healing but found no signiﬁcant differences
in mortality rates between HBOT and routine burn
management (RR 0.98, 95% CI 0.37–2.64). Also, no sig-
niﬁcant differences in length of hospital stay or number of
surgeries were found. However, we did not have access to
the original data and therefore could not reanalyze it. Hart
et al. reported a signiﬁcantly lower mean healing time in
the HBOT-treated group (mean 19.7 days) than in the
sham-HBOT group (mean 43.8 days) (P\0.005). No SDs
were given to check this result. No deaths were observed.
Three patients in the HBOT group experienced sinus bar-
otrauma, and one patient in the control group had transient
viremia during the treatment.
Split-skin grafts
Perrins studied HBOT applied to patients who had under-
gone a split-skin graft (SSG) [18]. In this British trial,
complete survival was deﬁned as 95% take of the graft.
Patients treated with HBOT had a signiﬁcantly higher per-
centage complete survival ([95% healthy graft area: RR
3.50; 95% CI 1.35–9.11; NNT 2). Consistently, he found
better results in the HBOT group, but two grafts (8%) in the
HBOT group failed completely versus no failures in the
control group (RR 5.00; 95% CI 0.25–98.96). However, this
was not signiﬁcantly different. Other secondary outcomes
were not reported for these SSGs.
Flap grafting
Xie and Li studied HBOT in patients with skin defects in
the limbs, for which they underwent ﬂap grafting [19]. In
Fig. 1 Flow of information
through the various phases of a
systematic review
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123this Chinese trial, no signiﬁcant differences in complete
ﬂap survival were found between HBOT and dexametha-
sone (RR 0.50, 95% CI 0.19–1.35) and between HBOT and
heparin (RR 0.42, 95% CI 0.16–1.09).
Discussion
This review shows that some evidence is available based
on robust study designs regarding the effectiveness of
HBOT for the management of acute wounds, although the
trials found were few and showed several methodologic
ﬂaws. Only ﬁve RCTs were found, the results of which
could not be pooled. However, based on individual trial
data, HBOT appears beneﬁcial in patients with crush
injuries, which show improved wound healing and less
adverse outcomes such as necrosis or the need for addi-
tional surgical procedures. Also, burns appear to heal
quicker with HBOT. Furthermore, HBOT appears to
improve the take of split-skin grafts. On the other hand,
complete wound healing is the most patient-relevant out-
come. Hence, incomplete graft take, leading to a mere
reduction in wound size, is not very meaningful.
Our ﬁndings are supported by those of previous reviews
by Goldman [10] and Wang et al. [5]. Their reviews
included studies with designs other than RCTs. Addition-
ally, burns were not included. They concluded that HBOT
may be beneﬁcial as an adjunctive therapy for compro-
mised skin grafts. In contrast, our review is based on ran-
domized evidence alone, using Cochrane Collaboration
methodology. It includes only studies with high internal
validity, which offers more robust evidence.
In the present review, two of the included studies were
published more than 35 years ago. However, the HBOT
technique is merely meant to compress air, and this tech-
nology has not changed since then. Hence, we do not think
that this time interval affects our conclusions.
One of the included trials reported some major adverse
effects in both treatment arms [15]. However, these cannot
be explained by a biological rationale and are therefore
unlikely to be due to HBOT. From larger descriptive
studies, we know that about 20% of patients experience
only mild adverse effects, such as some degree of middle
ear barotrauma, and 60 to 70% of them suffer from mea-
surable, but reversible, worsening myopia [20].
The body of evidence on the usefulness of HBOT is
larger for chronic wounds than for acute wounds [6, 8, 21].
Chronic wounds generally have poor local perfusion,
which hampers wound healing. This may be counteracted
by HBOT. Similarly, with ischemic acute wounds such as
crush injuries, HBOT can be effective in overcoming an
initial period of local ischemia underlying the problematic
healing of these wounds. On the other hand, acute wounds
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123are more difﬁcult to treat with HBOT because of their
urgency and the limited availability of HBOT facilities.
Thus, the application of HBOT can be justiﬁed only if the
cost is acceptable and HBOT facilities are available at the
time of presentation. Hence, it would be bold to advocate
the routine use of HBOT for such wounds. In addition,
patient selection should be done carefully and according to
local guidelines for recognized and reimbursed indications
for HBOT [22, 23] (Table 3). On the other hand, HBOT is
rather widely available in North America—with more than
300 facilities registered with the Undersea and Hyperbaric
Medical Society (UHMS)—Russia, China, and Cuba; it is
less well established in Europe and Australasia [24].
Further evaluation through well designed and well
conducted RCTs is needed to corroborate clinically rele-
vant effects of HBOT. Patients suitable for HBOT require
repeated treatments and depend on availability. These
appear to be predominant reasons why RCTs on HBOT,
particularly for acute wounds, may be difﬁcult to perform.
However, the number of HBO chambers is increasing,
which expands the availability of the treatment. Acute
conditions possibly of interest for future studies are ﬂaps
used in plastic surgery, calciphylaxis, and jaw surgery
because in these circumstances oxygen perfusion can be
severely hampered. In such cases, wound healing is at risk,
and wound infections are more likely to occur. Currently,
an RCT is ongoing to investigate the efﬁcacy of adding
HBOT to the treatment of late radiation damage of the
lower jaw (osteoradionecrosis) (http:\\www.clinicaltrials.
gov/, NCT00989820). Present-day reality is that cost-
effectiveness studies are lacking [25], and transportation
logistics may preclude the use of HBOT during an early
phase of wound healing of acute surgical and traumatic
wounds. Nevertheless, if a HBOT facility is at hand, the
evidence found in this review supports its application for
acute, difﬁcult to heal wounds.
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